[8-K] ANGIODYNAMICS INC Reports Material Event
AngioDynamics reported fiscal Q3 2026 results showing solid Med Tech–led growth but continued GAAP losses.
Rhea-AI Filing Summary
AngioDynamics reported fiscal Q3 2026 results showing solid Med Tech–led growth but continued GAAP losses. Net sales were $78.4 million, up 8.9% year over year, with Med Tech revenue of $37.3 million growing 19.0% and Med Device revenue of $41.1 million up 1.1%.
Gross margin was 52.9%, down 110 basis points, reflecting tariffs, inflation and manufacturing transition costs. The company posted a GAAP net loss of $8.1 million, or ($0.19) per share, and a pro forma adjusted net loss of $3.0 million, or ($0.07) per share, while pro forma adjusted EBITDA improved to $1.8 million.
AngioDynamics ended the quarter with $37.8 million in cash and no debt. It raised full-year 2026 guidance, now expecting net sales of $313.5–$315.5 million, Med Tech growth of 15–17%, adjusted EBITDA of $10.0–$12.0 million, and adjusted EPS between ($0.30) and ($0.23).
Positive
- None.
Negative
- None.
Insights
Med Tech strength and higher 2026 guidance offset margin and cash headwinds.
AngioDynamics delivered Q3 2026 net sales of $78.4M, up 8.9% year over year, driven by Med Tech revenue of $37.3M growing 19.0%. Auryon, mechanical thrombectomy and NanoKnife all posted high-teens to low-20s growth, underscoring strong adoption of the company’s newer technologies.
Profitability remains mixed. Gross margin slipped to 52.9%, 110 basis points lower, primarily from tariffs, inflation and manufacturing transition costs. GAAP net loss was $8.1M, but pro forma adjusted EBITDA improved to $1.8M, up from $1.3M a year earlier, showing better underlying earnings power.
Management raised full-year 2026 guidance, targeting net sales of $313.5–$315.5M, Med Tech growth of 15–17%, and adjusted EBITDA of $10–$12M. They plan to accelerate $3–$5M of inventory build in Q4 to mitigate vendor sterilization shutdowns, which may leave full-year cash flow slightly negative but is framed as timing rather than a shift in the longer-term cash generation profile.
8-K Event Classification
3 items: 2.02, 7.01, 9.01
3 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 2, 2026
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(518 ) 795-1400
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 – Results of Operations and Financial Condition.
On April 2, 2026, AngioDynamics, Inc. (“AngioDynamics”) issued a press release announcing financial results for the fiscal third quarter
ended February 28, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing under the Securities
Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 7.01 – Regulation FD Disclosure.
Presentation slides discussing AngioDynamics and its fiscal third quarter ended February 28, 2026 are furnished herewith as Exhibit 99.2.
The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.2) shall not be deemed “filed” for
purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange
Act.
Forward-Looking Statements
This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and
objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “projects”, “optimistic,” or variations of such words
and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially
from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its
existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to
effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical
trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party
distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the
effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of
AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form
10-K for the year ended May 31, 2025. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
Item 9.01 – Financial Statements and Exhibits.
|
(d)
|
Exhibits.
|
|
Exhibit No.
|
Description
|
|
99.1
|
Press Release, dated April 2, 2026.
|
|
99.2
|
Presentation, dated April 2, 2026.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
|
ANGIODYNAMICS, INC.
|
|||
|
(Registrant)
|
|||
|
Date: April 2, 2026
|
By: | /s/ Lawrence T. Weiss | |
|
Name:
|
Lawrence T. Weiss | ||
|
Title:
|
Senior Vice President, Chief Legal Officer and Corporate Secretary
|
Exhibit 99.1
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued
Profitability
| • |
Med Tech segment delivered its sixth consecutive quarter of double-digit growth
|
| • |
Strong adjusted EBITDA
|
| • |
Third consecutive quarter the Company raised full year FY 2026 guidance for net sales and Adjusted EBITDA
|
LATHAM, N.Y.--(BUSINESS WIRE)— April 2, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy
blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2026, which ended February 28, 2026.
Fiscal Year 2026 Third Quarter Highlights
|
Quarter Ended
February 28, 2026
|
Pro Forma* YoY Growth
|
|
|
Net Sales
|
$78.4 million
|
8.9%
|
|
Med Tech Net Sales
|
$37.3 million
|
19.0%
|
|
Med Device Net Sales
|
$41.1 million
|
1.1%
|
| • |
GAAP gross margin of 52.9%
|
| • |
GAAP loss per share of $0.19
|
| • |
Adjusted loss per share of $0.07
|
| • |
Adjusted EBITDA of $1.8 million
|
| • |
Ended fiscal 2026 third quarter with $37.8 million in cash, in line with expectations
|
*Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023 and the PICC, Midline and tip location product portfolios
divested in February 2024, as well as the discontinued Radiofrequency and Syntrax support catheter products in February 2024.
"We delivered a strong quarter, driven by continued execution across the organization, allowing us to deliver yet another quarter of profitable growth," commented Jim
Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. "Our mechanical thrombectomy portfolio exhibited standout performance as commercial adoption continues to build with both AlphaVac and AngioVac, confirming our belief that we
have the strongest mechanical thrombectomy portfolio available. Auryon remains a consistent growth driver, and NanoKnife is accelerating adoption as we see our commercial strategy supported by the recently effective CPT 1 code for prostate. Beyond
the demonstrated topline growth in our higher margin Med Tech businesses, the disciplined execution of our operating initiatives translated into another quarter of strong positive adjusted EBITDA."
Mr. Clemmer continued, "Our year-to-date performance gives us confidence in our ability to continue to deliver on our strategy and vision. The progress we have made over
the past several years is showing up in our results, and we remain focused on driving sustained, profitable growth as we head into the fourth quarter and fiscal 2027."
1
Fiscal Year 2026 Third Quarter Financial Results
Unless otherwise noted, all financial comparisons below are presented on a pro forma basis excluding the Dialysis and BioSentry businesses divested in June 2023, the
PICC, Midline, and tip location product portfolios divested in February 2024, and the RadioFrequency and Syntrax support catheter products discontinued in February 2024.
Net sales for the third quarter of fiscal year 2026 were $78.4 million, an increase of 8.9% compared to the prior-year quarter.
Med Tech net sales were $37.3 million, a 19.0% increase from $31.3 million in the prior-year period. Med Tech includes the Auryon peripheral atherectomy platform, our
thrombus management platform which is led by AlphaVac and AngioVac, and the NanoKnife irreversible electroporation platform.
Growth during the quarter was driven by solid performance across the Med Tech segment. Auryon sales were $16.3 million, an increase of 17.9% compared to the prior-year
quarter, our Mechanical Thrombectomy business, which includes AngioVac and AlphaVac, delivered sales of $11.5 million, an increase of 17.9% compared to the prior-year quarter, and NanoKnife sales were $7.6 million, an increase of 21.0% compared to
the prior-year quarter, including 20.0% growth in probes and 24.9% growth in capital sales.
Med Device net sales were $41.1 million, a 1.1% increase compared to $40.7 million in the prior-year period.
Gross margin for the third quarter of fiscal 2026 was 52.9%, which was 110 basis points lower compared to the third quarter of fiscal 2025, primarily driven by the impact and timing of tariffs, increased inflation and certain costs associated with the Company’s manufacturing transition, all of which were in-line with the Company’s
expectations.
The Company recorded a GAAP net loss of $8.1 million, or a loss per share of $0.19, in the third quarter of fiscal 2026. Excluding the items shown in the
non-GAAP reconciliation table below, adjusted net loss for the third quarter of fiscal 2026 was $3.0 million, or a loss per share of $0.07. This compares to an adjusted net loss during the fiscal third quarter of 2025 of $3.1 million, or a loss per share of $0.08.
Adjusted EBITDA in the third quarter of fiscal 2026, excluding the items shown in the
non-GAAP reconciliation table below, was $1.8 million, compared to $1.3 million in the third quarter of fiscal 2025.
Tariff related expenses were $1.3 million during the quarter, compared to zero for the prior year quarter, in-line with the Company’s expectations.
In the third quarter of fiscal 2026, the Company used $3.0 million of cash, slightly less than the Company’s expectations.
At February 28, 2026, the Company had $37.8 million in cash and maintains a debt-free balance sheet.
2
Fiscal Year 2026 Financial Guidance
For fiscal year 2026 the Company now expects:
|
Guidance Metric
|
Guidance Action
|
Current Guidance
(as of April 2, 2026)
|
Previous Guidance
(as of January 6, 2026)
|
|
Net Sales
|
Increased
|
$313.5 - $315.5 M
|
$312 - $314 M
|
|
Med Tech Net Sales Growth
|
Increased
|
15% - 17%
|
14% - 16%
|
|
Med Device Net Sales Growth
|
Increased
|
Approx. 1%
|
0% - 1%
|
|
Gross Margin
|
Unchanged
|
53.5% - 55.5%
|
53.5% - 55.5%
|
|
Adjusted EBITDA
|
Increased
|
$10.0 - $12.0 M
|
$8.0 - $10.0 M
|
|
Adjusted EPS
|
Increased
|
($0.30) – ($0.23)
|
($0.33) – ($0.23)
|
Cash Flow Guidance
The Company remains on course to illustrate that its business model will be cash flow positive and expects to generate substantial cash in the fourth fiscal
quarter, in line with historical trends. During the third fiscal quarter, the Company was advised by its sterilization vendors of their plan to implement two upcoming temporary shutdowns to perform maintenance activities during the fourth quarter. To
proactively address this and avoid any potential commercial disruptions, the Company plans to increase inventory levels for certain products during the fourth quarter. The net result will be the acceleration of the use of approximately $3.0 to $5.0
million of cash to build inventory in the back half of fiscal year 2026, which normally would have been used in future periods. This may result in cash flow for fiscal year 2026 being slightly negative. The Company noted that there is no modification
to the positive cash generation pathway that it has been on or the cash generation profile of the business.
Tariff Related Guidance Assumptions
For the full fiscal year 2026, the Company continues to expect a $4.0 - $6.0 million impact from tariffs, which are included in the above provided
guidance.
All assumptions made related to expected tariff impacts are based on the Company’s point of view on the current tariff situation, as of April 2, 2026. As
the situation is fluid, these assumptions may change in the future.
Conference Call
The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, dial
1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be
available at the same site approximately one hour after the end of the call.
3
A recording of the call will also be available, until Thursday, April 9, 2026 at 11:59 PM ET. To hear this recording, dial 1-844-512-2921 (domestic) or
+1-412-317-6671 (international) and enter the passcode 13758776.
Use of Non-GAAP Measures
Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying
trends in AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release,
AngioDynamics has reported pro forma results, adjusted EBITDA, adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these
measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics'
underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only occur
from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.
About AngioDynamics, Inc.
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding
cancer treatment options and improving quality of life for patients.
The Company’s innovative technologies and devices are chosen by talented physicians in
fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
Safe Harbor
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding
AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for
future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects," "optimistic," or variations of such words and similar expressions, are
forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics'
expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new
products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively
compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials,
overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or
joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic,
credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain
regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year
ended May 31, 2025. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
4
Investors:
Stephen Trowbridge
Executive Vice President & CFO
518-795-1408
strowbridge@angiodynamics.com
Media:
Saleem Cheeks
Vice President, Communications
518-795-1174
scheeks@angiodynamics.com
5
ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENTS
(in thousands, except per share data)
|
Three Months Ended
|
||||||||||||||||||||||||
|
Actual (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
|||||||||||||||||||
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2025
|
Feb 28, 2025
|
Feb 28, 2025
|
|||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||
|
Net sales
|
$
|
78,423
|
(2
|
)
|
$
|
78,421
|
$
|
72,004
|
9
|
$
|
72,013
|
|||||||||||||
|
Cost of sales (exclusive of intangible amortization)
|
36,944
|
—
|
36,944
|
33,147
|
6
|
33,153
|
||||||||||||||||||
|
Gross margin
|
41,479
|
(2
|
)
|
41,477
|
38,857
|
3
|
38,860
|
|||||||||||||||||
|
% of net sales
|
52.9
|
%
|
52.9
|
%
|
54.0
|
%
|
54.0
|
%
|
||||||||||||||||
|
Operating expenses
|
||||||||||||||||||||||||
|
Research and development
|
7,084
|
—
|
7,084
|
6,913
|
—
|
6,913
|
||||||||||||||||||
|
Sales and marketing
|
27,437
|
—
|
27,437
|
25,504
|
—
|
25,504
|
||||||||||||||||||
|
General and administrative
|
10,719
|
—
|
10,719
|
10,490
|
—
|
10,490
|
||||||||||||||||||
|
Amortization of intangibles
|
2,668
|
—
|
2,668
|
2,598
|
—
|
2,598
|
||||||||||||||||||
|
Change in fair value of contingent consideration
|
—
|
—
|
—
|
40
|
—
|
40
|
||||||||||||||||||
|
Acquisition, restructuring and other items, net
|
6,522
|
—
|
6,522
|
3,286
|
(3
|
)
|
3,283
|
|||||||||||||||||
|
Total operating expenses
|
54,430
|
—
|
54,430
|
48,831
|
(3
|
)
|
48,828
|
|||||||||||||||||
|
Operating loss
|
(12,951
|
)
|
(2
|
)
|
(12,953
|
)
|
(9,974
|
)
|
6
|
(9,968
|
)
|
|||||||||||||
|
Interest income (expense), net
|
(88
|
)
|
—
|
(88
|
)
|
135
|
—
|
135
|
||||||||||||||||
|
Other income (expense), net
|
4,967
|
(5,000
|
)
|
(33
|
)
|
5,430
|
(5,500
|
)
|
(70
|
)
|
||||||||||||||
|
Total other income (expense), net
|
4,879
|
(5,000
|
)
|
(121
|
)
|
5,565
|
(5,500
|
)
|
65
|
|||||||||||||||
|
Loss before income tax (benefit) expense
|
(8,072
|
)
|
(5,002
|
)
|
(13,074
|
)
|
(4,409
|
)
|
(5,494
|
)
|
(9,903
|
)
|
||||||||||||
|
Income tax (benefit) expense
|
12
|
—
|
12
|
(2
|
)
|
—
|
(2
|
)
|
||||||||||||||||
|
Net loss
|
$
|
(8,084
|
)
|
$
|
(5,002
|
)
|
$
|
(13,086
|
)
|
$
|
(4,407
|
)
|
$
|
(5,494
|
)
|
$
|
(9,901
|
)
|
||||||
|
Loss per share
|
||||||||||||||||||||||||
|
Basic
|
$
|
(0.19
|
)
|
$
|
(0.31
|
)
|
$
|
(0.11
|
)
|
$
|
(0.24
|
)
|
||||||||||||
|
Diluted
|
$
|
(0.19
|
)
|
$
|
(0.31
|
)
|
$
|
(0.11
|
)
|
$
|
(0.24
|
)
|
||||||||||||
|
Weighted average shares outstanding
|
||||||||||||||||||||||||
|
Basic
|
41,596
|
41,596
|
40,853
|
40,853
|
||||||||||||||||||||
|
Diluted
|
41,596
|
41,596
|
40,853
|
40,853
|
||||||||||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on
June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 28, 2026 and
February 28, 2025.
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
6
ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENTS
(in thousands, except per share data)
|
Nine Months Ended
|
||||||||||||||||||||||||
|
Actual (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
|||||||||||||||||||
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2025
|
Feb 28, 2025
|
Feb 28, 2025
|
|||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||
|
Net sales
|
$
|
233,567
|
(2
|
)
|
$
|
233,565
|
$
|
212,340
|
188
|
$
|
212,528
|
|||||||||||||
|
Cost of sales (exclusive of intangible amortization)
|
105,448
|
—
|
105,448
|
96,853
|
155
|
97,008
|
||||||||||||||||||
|
Gross margin
|
128,119
|
(2
|
)
|
128,117
|
115,487
|
33
|
115,520
|
|||||||||||||||||
|
% of net sales
|
54.9
|
%
|
54.9
|
%
|
54.4
|
%
|
54.4
|
%
|
||||||||||||||||
|
Operating expenses
|
||||||||||||||||||||||||
|
Research and development
|
21,269
|
—
|
21,269
|
19,632
|
—
|
19,632
|
||||||||||||||||||
|
Sales and marketing
|
82,278
|
—
|
82,278
|
76,698
|
—
|
76,698
|
||||||||||||||||||
|
General and administrative
|
33,425
|
—
|
33,425
|
31,856
|
—
|
31,856
|
||||||||||||||||||
|
Amortization of intangibles
|
7,964
|
—
|
7,964
|
7,730
|
—
|
7,730
|
||||||||||||||||||
|
Change in fair value of contingent consideration
|
—
|
—
|
—
|
272
|
—
|
272
|
||||||||||||||||||
|
Acquisition, restructuring and other items, net
|
12,915
|
—
|
12,915
|
13,465
|
161
|
13,626
|
||||||||||||||||||
|
Total operating expenses
|
157,851
|
—
|
157,851
|
149,653
|
161
|
149,814
|
||||||||||||||||||
|
Operating loss
|
(29,732
|
)
|
(2
|
)
|
(29,734
|
)
|
(34,166
|
)
|
(128
|
)
|
(34,294
|
)
|
||||||||||||
|
Interest income (expense), net
|
(194
|
)
|
—
|
(194
|
)
|
975
|
—
|
975
|
||||||||||||||||
|
Other income (expense), net
|
4,661
|
(5,000
|
)
|
(339
|
)
|
5,269
|
(5,500
|
)
|
(231
|
)
|
||||||||||||||
|
Total other income (expense), net
|
4,467
|
(5,000
|
)
|
(533
|
)
|
6,244
|
(5,500
|
)
|
744
|
|||||||||||||||
|
Loss before income tax expense
|
(25,265
|
)
|
(5,002
|
)
|
(30,267
|
)
|
(27,922
|
)
|
(5,628
|
)
|
(33,550
|
)
|
||||||||||||
|
Income tax expense
|
72
|
—
|
72
|
21
|
—
|
21
|
||||||||||||||||||
|
Net loss
|
$
|
(25,337
|
)
|
$
|
(5,002
|
)
|
$
|
(30,339
|
)
|
$
|
(27,943
|
)
|
$
|
(5,628
|
)
|
$
|
(33,571
|
)
|
||||||
|
Loss per share
|
||||||||||||||||||||||||
|
Basic
|
$
|
(0.61
|
)
|
$
|
(0.73
|
)
|
$
|
(0.68
|
)
|
$
|
(0.82
|
)
|
||||||||||||
|
Diluted
|
$
|
(0.61
|
)
|
$
|
(0.73
|
)
|
$
|
(0.68
|
)
|
$
|
(0.82
|
)
|
||||||||||||
|
Weighted average shares outstanding
|
||||||||||||||||||||||||
|
Basic
|
41,467
|
41,467
|
40,809
|
40,809
|
||||||||||||||||||||
|
Diluted
|
41,467
|
41,467
|
40,809
|
40,809
|
||||||||||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on
June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the nine months ended February 28, 2026 and
February 28, 2025.
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
7
ANGIODYNAMICS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION
(in thousands, except per share data)
Reconciliation of Net Loss to non-GAAP Adjusted Net Income (Loss) and Pro Forma Adjusted Net Loss:
|
Three Months Ended
|
||||||||||||||||||||||||
|
Actual(1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
|||||||||||||||||||
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2025
|
Feb 28, 2025
|
Feb 28, 2025
|
|||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||
|
Net loss
|
$
|
(8,084
|
)
|
$
|
(5,002
|
)
|
$
|
(13,086
|
)
|
$
|
(4,407
|
)
|
$
|
(5,494
|
)
|
$
|
(9,901
|
)
|
||||||
|
Amortization of intangibles
|
2,668
|
—
|
2,668
|
2,598
|
—
|
2,598
|
||||||||||||||||||
|
Change in fair value of contingent consideration
|
—
|
—
|
—
|
40
|
—
|
40
|
||||||||||||||||||
|
Acquisition, restructuring and other items, net (3)
|
6,522
|
—
|
6,522
|
3,286
|
(3
|
)
|
3,283
|
|||||||||||||||||
|
Tax effect of non-GAAP items (4)
|
(245
|
)
|
1,150
|
905
|
(350
|
)
|
1,264
|
914
|
||||||||||||||||
|
Adjusted net income (loss)
|
$
|
861
|
$
|
(3,852
|
)
|
$
|
(2,991
|
)
|
$
|
1,167
|
$
|
(4,233
|
)
|
$
|
(3,066
|
)
|
||||||||
Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted and Pro Forma Adjusted Diluted Income (Loss) Per Share:
|
Three Months Ended
|
||||||||||||||||||||||||
|
Actual(1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
|||||||||||||||||||
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2025
|
Feb 28, 2025
|
Feb 28, 2025
|
|||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||
|
Diluted loss per share
|
$
|
(0.19
|
)
|
$
|
(0.12
|
)
|
$
|
(0.31
|
)
|
$
|
(0.11
|
)
|
$
|
(0.13
|
)
|
$
|
(0.24
|
)
|
||||||
|
Amortization of intangibles
|
0.06
|
—
|
0.06
|
0.06
|
—
|
0.06
|
||||||||||||||||||
|
Change in fair value of contingent consideration
|
—
|
—
|
—
|
0.01
|
—
|
0.01
|
||||||||||||||||||
|
Acquisition, restructuring and other items, net (3)
|
0.16
|
—
|
0.16
|
0.08
|
(0.01
|
)
|
0.07
|
|||||||||||||||||
|
Tax effect of non-GAAP items (4)
|
(0.01
|
)
|
0.03
|
0.02
|
(0.01
|
)
|
0.03
|
0.02
|
||||||||||||||||
|
Adjusted diluted income (loss) per share
|
$
|
0.02
|
$
|
(0.09
|
)
|
$
|
(0.07
|
)
|
$
|
0.03
|
$
|
(0.11
|
)
|
$
|
(0.08
|
)
|
||||||||
|
Adjusted diluted sharecount (5)
|
43,752
|
41,596
|
41,596
|
42,091
|
40,853
|
40,853
|
||||||||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on
June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 28, 2026 and
2025, respectively .
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain
litigation, and other items.
(4) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax
assets and an effective tax rate of 23% for the periods ended February 28, 2026 and 2025.
(5) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.
8
ANGIODYNAMICS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION (Continued)
(in thousands)
Reconciliation of Net Loss and non-GAAP Pro Forma Adjusted Net Loss to Adjusted EBITDA and Pro Forma Adjusted EBITDA:
|
Three Months Ended
|
||||||||||||||||||||||||
|
As Reported (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
|||||||||||||||||||
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2025
|
Feb 28, 2025
|
Feb 28, 2025
|
|||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||
|
Net loss
|
$
|
(8,084
|
)
|
$
|
(5,002
|
)
|
$
|
(13,086
|
)
|
$
|
(4,407
|
)
|
$
|
(5,494
|
)
|
$
|
(9,901
|
)
|
||||||
|
Income tax expense
|
12
|
—
|
12
|
(2
|
)
|
—
|
(2
|
)
|
||||||||||||||||
|
Interest expense (income), net
|
88
|
—
|
88
|
(135
|
)
|
—
|
(135
|
)
|
||||||||||||||||
|
Depreciation and amortization
|
5,591
|
—
|
5,591
|
6,319
|
—
|
6,319
|
||||||||||||||||||
|
Change in fair value of contingent consideration
|
—
|
—
|
—
|
40
|
—
|
40
|
||||||||||||||||||
|
Stock based compensation
|
2,684
|
—
|
2,684
|
2,398
|
—
|
2,398
|
||||||||||||||||||
|
Acquisition, restructuring and other items, net (3)
|
6,522
|
—
|
6,522
|
2,623
|
(3
|
)
|
2,620
|
|||||||||||||||||
|
Adjusted EBITDA
|
$
|
6,813
|
$
|
(5,002
|
)
|
$
|
1,811
|
$
|
6,836
|
$
|
(5,497
|
)
|
$
|
1,339
|
||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on
June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 28, 2026 and
2025, respectively .
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain
litigation, and other items.
9
ANGIODYNAMICS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION
(in thousands, except per share data)
Reconciliation of Net Loss to non-GAAP Adjusted Net Loss and Pro Forma Adjusted Net Loss:
|
Nine Months Ended
|
||||||||||||||||||||||||
|
As Reported (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
|||||||||||||||||||
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2025
|
Feb 28, 2025
|
Feb 28, 2025
|
|||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||
|
Net loss
|
$
|
(25,337
|
)
|
$
|
(5,002
|
)
|
$
|
(30,339
|
)
|
$
|
(27,943
|
)
|
$
|
(5,628
|
)
|
$
|
(33,571
|
)
|
||||||
|
Amortization of intangibles
|
7,964
|
—
|
7,964
|
7,730
|
—
|
7,730
|
||||||||||||||||||
|
Change in fair value of contingent consideration
|
—
|
—
|
—
|
272
|
—
|
272
|
||||||||||||||||||
|
Acquisition, restructuring and other items, net (3)
|
12,915
|
—
|
12,915
|
13,465
|
161
|
13,626
|
||||||||||||||||||
|
Tax effect of non-GAAP items (4)
|
1,081
|
1,150
|
2,231
|
1,506
|
1,257
|
2,763
|
||||||||||||||||||
|
Adjusted net loss
|
$
|
(3,377
|
)
|
$
|
(3,852
|
)
|
$
|
(7,229
|
)
|
$
|
(4,970
|
)
|
$
|
(4,210
|
)
|
$
|
(9,180
|
)
|
||||||
Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted and Pro Forma Adjusted Diluted Loss Per Share:
|
Nine Months Ended
|
||||||||||||||||||||||||
|
As Reported (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
|||||||||||||||||||
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2025
|
Feb 28, 2025
|
Feb 28, 2025
|
|||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||
|
Diluted loss per share
|
$
|
(0.61
|
)
|
$
|
(0.12
|
)
|
(0.73
|
)
|
(0.68
|
)
|
$
|
(0.14
|
)
|
(0.82
|
)
|
|||||||||
|
Amortization of intangibles
|
0.19
|
—
|
0.19
|
0.19
|
$
|
—
|
0.19
|
|||||||||||||||||
|
Change in fair value of contingent consideration
|
—
|
—
|
—
|
0.01
|
$
|
—
|
0.01
|
|||||||||||||||||
|
Acquisition, restructuring and other items, net (3)
|
0.31
|
—
|
0.31
|
0.32
|
$
|
0.01
|
0.33
|
|||||||||||||||||
|
Tax effect of non-GAAP items (4)
|
0.03
|
0.03
|
0.06
|
0.04
|
$
|
0.03
|
0.07
|
|||||||||||||||||
|
Adjusted diluted loss per share
|
$
|
(0.08
|
)
|
$
|
(0.09
|
)
|
$
|
(0.17
|
)
|
$
|
(0.12
|
)
|
$
|
(0.10
|
)
|
$
|
(0.22
|
)
|
||||||
|
|
||||||||||||||||||||||||
|
Adjusted diluted sharecount (5)
|
41,467
|
41,467
|
41,467
|
40,809
|
40,809
|
40,809
|
||||||||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on
June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the nine months ended February 28, 2026 and
2025, respectively .
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain
litigation, and other items.
(4) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax
assets and an effective tax rate of 23% for the periods ended February 28, 2026 and 2025.
(5) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.
10
ANGIODYNAMICS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION (Continued)
(in thousands)
Reconciliation of Net Loss and non-GAAP Pro Forma Net Loss to Adjusted EBITDA and Pro Forma Adjusted EBITDA:
|
Nine Months Ended
|
||||||||||||||||||||||||
|
As Reported (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
|||||||||||||||||||
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2025
|
Feb 28, 2025
|
Feb 28, 2025
|
|||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||
|
Net loss
|
$
|
(25,337
|
)
|
$
|
(5,002
|
)
|
$
|
(30,339
|
)
|
$
|
(27,943
|
)
|
$
|
(5,628
|
)
|
$
|
(33,571
|
)
|
||||||
|
Income tax expense
|
72
|
—
|
$
|
72
|
21
|
—
|
$
|
21
|
||||||||||||||||
|
Interest expense (income), net
|
194
|
—
|
$
|
194
|
(975
|
)
|
—
|
$
|
(975
|
)
|
||||||||||||||
|
Depreciation and amortization
|
17,358
|
—
|
$
|
17,358
|
19,967
|
—
|
$
|
19,967
|
||||||||||||||||
|
Change in fair value of contingent consideration
|
—
|
—
|
$
|
—
|
272
|
—
|
$
|
272
|
||||||||||||||||
|
Stock based compensation
|
10,045
|
—
|
$
|
10,045
|
8,131
|
—
|
$
|
8,131
|
||||||||||||||||
|
Acquisition, restructuring and other items, net (3)
|
12,578
|
—
|
$
|
12,578
|
10,239
|
161
|
$
|
10,400
|
||||||||||||||||
|
Adjusted EBITDA
|
$
|
14,910
|
$
|
(5,002
|
)
|
$
|
9,908
|
$
|
9,712
|
$
|
(5,467
|
)
|
$
|
4,245
|
||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on
June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the nine months ended February 28, 2026 and
2025, respectively .
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
(3) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain
litigation, and other items.
11
ANGIODYNAMICS, INC. AND SUBSIDIARIES
ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET DETAIL
(in thousands)
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
Feb 28, 2026
|
Feb 28, 2025
|
Feb 28, 2026
|
Feb 28, 2025
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||
|
Legal (1)
|
$
|
146
|
$
|
—
|
$
|
1,831
|
$
|
406
|
||||||||
|
Mergers and acquisitions
|
—
|
—
|
—
|
737
|
||||||||||||
|
Plant closure (2)
|
5,195
|
3,130
|
9,911
|
11,820
|
||||||||||||
|
Transition service agreement (3)
|
(555
|
)
|
(463
|
)
|
(1,523
|
)
|
(1,424
|
)
|
||||||||
|
CEO retirement and transition(4)
|
870
|
—
|
870
|
—
|
||||||||||||
|
Other
|
866
|
619
|
1,826
|
1,926
|
||||||||||||
|
Total
|
$
|
6,522
|
$
|
3,286
|
$
|
12,915
|
$
|
13,465
|
||||||||
(1) Legal expenses related to litigation that is outside the normal course of business.
(2) Plant closure expense, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024.
(3) Transition services agreements that were entered into with Merit and Spectrum.
(4) CEO retirement and transition expenses related to the CEO search and retention agreements with the Company's executive leadership team.
12
ANGIODYNAMICS, INC. AND SUBSIDIARIES
NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY
(in thousands)
|
Three Months Ended
|
||||||||||||||||||||||||||||||||
|
Pro Forma
Adjustments (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma
Adjustments (2)
|
Pro Forma
|
Actual
|
Pro Forma
|
||||||||||||||||||||||||||
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2025
|
Feb 28, 2025
|
Feb 28, 2025
|
% Growth
|
% Growth
|
|||||||||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||||||||||
|
Net Sales
|
||||||||||||||||||||||||||||||||
|
Med Tech
|
$
|
37,282
|
$
|
—
|
$
|
37,282
|
$
|
31,341
|
$
|
—
|
$
|
31,341
|
19.0
|
%
|
19.0
|
%
|
||||||||||||||||
|
Med Device
|
41,141
|
(2
|
)
|
41,139
|
40,663
|
9
|
40,672
|
1.2
|
%
|
1.1
|
%
|
|||||||||||||||||||||
|
$
|
78,423
|
$
|
(2
|
)
|
$
|
78,421
|
$
|
72,004
|
$
|
9
|
$
|
72,013
|
8.9
|
%
|
8.9
|
%
|
||||||||||||||||
|
Net Sales
|
||||||||||||||||||||||||||||||||
|
United States
|
$
|
67,278
|
$
|
(2
|
)
|
$
|
67,276
|
$
|
61,340
|
$
|
4
|
$
|
61,344
|
9.7
|
%
|
9.7
|
%
|
|||||||||||||||
|
International
|
11,145
|
—
|
11,145
|
10,664
|
5
|
10,669
|
4.5
|
%
|
4.5
|
%
|
||||||||||||||||||||||
|
$
|
78,423
|
$
|
(2
|
)
|
$
|
78,421
|
$
|
72,004
|
$
|
9
|
$
|
72,013
|
8.9
|
%
|
8.9
|
%
|
||||||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on
June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 28, 2025.
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
GROSS MARGIN BY PRODUCT CATEGORY
(in thousands)
|
Three Months Ended
|
||||||||||||||||||||||||||||||||
|
Pro Forma
Adjustments (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma
Adjustments (2)
|
Pro Forma
|
Actual
|
Pro Forma
|
||||||||||||||||||||||||||
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2025
|
Feb 28, 2025
|
Feb 28, 2025
|
% Change
|
% Change
|
|||||||||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||||||||||
|
Med Tech
|
$
|
23,292
|
$
|
—
|
$
|
23,292
|
$
|
19,588
|
$
|
—
|
$
|
19,588
|
18.9
|
%
|
18.9
|
%
|
||||||||||||||||
|
Gross margin % of sales
|
62.5
|
%
|
62.5
|
%
|
62.5
|
%
|
62.5
|
%
|
||||||||||||||||||||||||
|
Med Device
|
$
|
18,187
|
$
|
(2
|
)
|
$
|
18,185
|
$
|
19,269
|
$
|
3
|
$
|
19,272
|
(5.6
|
)%
|
(5.6
|
)%
|
|||||||||||||||
|
Gross margin % of sales
|
44.2
|
%
|
44.2
|
%
|
47.4
|
%
|
47.4
|
%
|
||||||||||||||||||||||||
|
Total
|
$
|
41,479
|
$
|
(2
|
)
|
$
|
41,477
|
$
|
38,857
|
$
|
3
|
$
|
38,860
|
6.7
|
%
|
6.7
|
%
|
|||||||||||||||
|
Gross margin % of sales
|
52.9
|
%
|
52.9
|
%
|
54.0
|
%
|
54.0
|
%
|
||||||||||||||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on
June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the three months ended February 28, 2025.
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
13
ANGIODYNAMICS, INC. AND SUBSIDIARIES
NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY
(in thousands)
|
Nine Months Ended
|
||||||||||||||||||||||||||||||||
|
Pro Forma
Adjustments (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma
Adjustments (2)
|
Pro Forma
|
Actual
|
Pro Forma
|
||||||||||||||||||||||||||
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2025
|
Feb 28, 2025
|
Feb 28, 2025
|
% Growth
|
% Growth
|
|||||||||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||||||||||
|
Net Sales
|
||||||||||||||||||||||||||||||||
|
Med Tech
|
$
|
108,196
|
$
|
—
|
$
|
108,196
|
$
|
90,863
|
$
|
—
|
$
|
90,863
|
19.1
|
%
|
19.1
|
%
|
||||||||||||||||
|
Med Device
|
125,371
|
(2
|
)
|
125,369
|
121,477
|
188
|
121,665
|
3.2
|
%
|
3.0
|
%
|
|||||||||||||||||||||
|
$
|
233,567
|
$
|
(2
|
)
|
$
|
233,565
|
$
|
212,340
|
$
|
188
|
$
|
212,528
|
10.0
|
%
|
9.9
|
%
|
||||||||||||||||
|
Net Sales
|
||||||||||||||||||||||||||||||||
|
United States
|
$
|
201,328
|
$
|
(2
|
)
|
$
|
201,326
|
$
|
183,499
|
$
|
14
|
$
|
183,513
|
9.7
|
%
|
9.7
|
%
|
|||||||||||||||
|
International
|
32,239
|
—
|
32,239
|
28,841
|
174
|
29,015
|
11.8
|
%
|
11.1
|
%
|
||||||||||||||||||||||
|
$
|
233,567
|
$
|
(2
|
)
|
$
|
233,565
|
$
|
212,340
|
$
|
188
|
$
|
212,528
|
10.0
|
%
|
9.9
|
%
|
||||||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on
June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the nine months ended February 28, 2025.
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
GROSS MARGIN BY PRODUCT CATEGORY
(in thousands)
|
Nine Months Ended
|
||||||||||||||||||||||||||||||||
|
Pro Forma
Adjustments (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma
Adjustments (2)
|
Pro Forma
|
Actual
|
Pro Forma
|
||||||||||||||||||||||||||
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2026
|
Feb 28, 2025
|
Feb 28, 2025
|
Feb 28, 2025
|
% Change
|
% Change
|
|||||||||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||||||||||
|
Med Tech
|
$
|
68,500
|
$
|
—
|
$
|
68,500
|
$
|
57,398
|
$
|
—
|
$
|
57,398
|
19.3
|
%
|
19.3
|
%
|
||||||||||||||||
|
Gross margin % of sales
|
63.3
|
%
|
63.3
|
%
|
63.2
|
%
|
63.2
|
%
|
||||||||||||||||||||||||
|
Med Device
|
$
|
59,619
|
$
|
(2
|
)
|
$
|
59,617
|
$
|
58,089
|
$
|
33
|
$
|
58,122
|
2.6
|
%
|
2.6
|
%
|
|||||||||||||||
|
Gross margin % of sales
|
47.6
|
%
|
47.6
|
%
|
47.8
|
%
|
47.8
|
%
|
||||||||||||||||||||||||
|
Total
|
$
|
128,119
|
$
|
(2
|
)
|
$
|
128,117
|
$
|
115,487
|
$
|
33
|
$
|
115,520
|
10.9
|
%
|
10.9
|
%
|
|||||||||||||||
|
Gross margin % of sales
|
54.9
|
%
|
54.9
|
%
|
54.4
|
%
|
54.4
|
%
|
||||||||||||||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on
June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") as of February 29, 2024, for the nine months ended February 28, 2025.
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
14
ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands)
|
Feb 28, 2026
|
May 31, 2025
|
|||||||
|
(unaudited)
|
(audited)
|
|||||||
|
Assets
|
||||||||
|
Current assets:
|
||||||||
|
Cash
|
$
|
37,810
|
$
|
55,893
|
||||
|
Accounts receivable, net
|
45,552
|
42,890
|
||||||
|
Inventories
|
58,578
|
62,006
|
||||||
|
Prepaid expenses and other
|
13,612
|
7,535
|
||||||
|
Total current assets
|
155,552
|
168,324
|
||||||
|
Property, plant and equipment, net
|
29,142
|
32,300
|
||||||
|
Other assets
|
10,498
|
10,404
|
||||||
|
Intangible assets, net
|
65,486
|
69,116
|
||||||
|
Total assets
|
$
|
260,678
|
$
|
280,144
|
||||
|
Liabilities and stockholders' equity
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
29,105
|
$
|
33,291
|
||||
|
Accrued liabilities
|
32,303
|
35,518
|
||||||
|
Other current liabilities
|
4,658
|
7,388
|
||||||
|
Total current liabilities
|
66,066
|
76,197
|
||||||
|
Deferred income taxes
|
4,554
|
4,073
|
||||||
|
Other long-term liabilities
|
16,701
|
16,904
|
||||||
|
Total liabilities
|
87,321
|
97,174
|
||||||
|
Stockholders' equity
|
173,357
|
182,970
|
||||||
|
Total Liabilities and Stockholders' Equity
|
$
|
260,678
|
$
|
280,144
|
||||
15
ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
|
Feb 28, 2026
|
Feb 28, 2025
|
Feb 28, 2026
|
Feb 28, 2025
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||
|
Cash flows from operating activities:
|
||||||||||||||||
|
Net loss
|
$
|
(8,084
|
)
|
$
|
(4,407
|
)
|
$
|
(25,337
|
)
|
$
|
(27,943
|
)
|
||||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||||||||||
|
Depreciation and amortization
|
5,591
|
6,319
|
17,358
|
19,967
|
||||||||||||
|
Non-cash lease expense
|
350
|
503
|
1,200
|
1,496
|
||||||||||||
|
Non-cash interest expense
|
72
|
—
|
217
|
—
|
||||||||||||
|
Stock based compensation
|
2,684
|
2,398
|
10,045
|
8,131
|
||||||||||||
|
Change in fair value of contingent consideration
|
—
|
40
|
—
|
272
|
||||||||||||
|
Deferred income taxes
|
57
|
(207
|
)
|
(7
|
)
|
(795
|
)
|
|||||||||
|
Change in accounts receivable allowances
|
317
|
142
|
190
|
530
|
||||||||||||
|
Fixed and intangible asset disposals
|
38
|
38
|
318
|
97
|
||||||||||||
|
Other
|
315
|
30
|
817
|
149
|
||||||||||||
|
Changes in operating assets and liabilities:
|
||||||||||||||||
|
Accounts receivable
|
(1,418
|
)
|
(474
|
)
|
(2,847
|
)
|
(424
|
)
|
||||||||
|
Inventories
|
7,057
|
2,810
|
3,584
|
(2,493
|
)
|
|||||||||||
|
Prepaid expenses and other
|
(4,077
|
)
|
(9,387
|
)
|
(6,372
|
)
|
(9,459
|
)
|
||||||||
|
Accounts payable, accrued and other liabilities
|
(6,012
|
)
|
(10,964
|
)
|
(13,529
|
)
|
(18,467
|
)
|
||||||||
|
Net cash used in operating activities
|
(3,110
|
)
|
(13,159
|
)
|
(14,363
|
)
|
(28,939
|
)
|
||||||||
|
Cash flows from investing activities:
|
||||||||||||||||
|
Additions to property, plant and equipment
|
(1,015
|
)
|
(1,798
|
)
|
(2,168
|
)
|
(3,687
|
)
|
||||||||
|
Additions to placement and evaluation units
|
(492
|
)
|
(1,391
|
)
|
(2,511
|
)
|
(3,868
|
)
|
||||||||
|
Net cash used in investing activities
|
(1,507
|
)
|
(3,189
|
)
|
(4,679
|
)
|
(7,555
|
)
|
||||||||
|
Cash flows from financing activities:
|
||||||||||||||||
|
Proceeds from financing arrangement
|
—
|
6,310
|
—
|
6,310
|
||||||||||||
|
Principal payments on finance arrangements
|
(95
|
)
|
(58
|
)
|
(278
|
)
|
(58
|
)
|
||||||||
|
Repurchase of common stock
|
—
|
—
|
—
|
(1,670
|
)
|
|||||||||||
|
Proceeds from exercise of stock options and employee stock purchase plan
|
716
|
895
|
950
|
933
|
||||||||||||
|
Net cash provided by financing activities
|
621
|
7,147
|
672
|
5,515
|
||||||||||||
|
Effect of exchange rate changes on cash
|
168
|
(128
|
)
|
287
|
(317
|
)
|
||||||||||
|
Decrease in cash
|
(3,828
|
)
|
(9,329
|
)
|
(18,083
|
)
|
(31,296
|
)
|
||||||||
|
Cash at beginning of period
|
41,638
|
54,089
|
55,893
|
76,056
|
||||||||||||
|
Cash at end of period
|
$
|
37,810
|
$
|
44,760
|
$
|
37,810
|
$
|
44,760
|
||||||||
16
Exhibit 99.2
